FDA approves Lynparza to treat BRCA-mutated breast cancer

The FDA has approved AstraZeneca's Lynparza, for treatment of BRCA-mutated breast cancer. This is the first drug to treat this type of cancer and the first for the new field of oncology medications known as PARP inhibitors.

This is also a boast for Merck which signed an $8.5 billion deal with AstraZeneca in July to share Lynparza and study the medication in combination with its own immunotherapy, Keytruda, as well as AstraZeneca's fellow PD-1, Imfinzi.

Click here to view the entire article.